RTSN Retension Pharmaceuticals, Inc.

Fundamentals / CIK 0002002988 / USD

Retension Pharmaceuticals, Inc. reported $14.15M in total assets through September 30, 2026 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open RTSN in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

No annual income statement rows are available in SEC EDGAR CompanyFacts for RTSN.

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Research & Development $5.02M -- -- $1.37M -- --
Total Operating Expenses $6.01M -- -- $1.66M -- --
Operating Income -$6.01M -- -- -$1.66M -- --
Interest Income $89K -- -- $189K -- --
Net Income -$5.92M -$4.14M -$3.38M -$1.48M -$1.23M -$656K
Basic EPS -$7.33 -- -- -$1.83 -- --
Diluted EPS -$7.33 -- -- -$1.83 -- --
Basic Shares Outstanding 807.9K -- -- 805.2K -- --
Diluted Shares Outstanding 807.9K -- -- 805.2K -- --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

No annual balance sheet rows are available in SEC EDGAR CompanyFacts for RTSN.

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2025-12-31
Cash & Cash Equivalents $9.19M $18.90M
Cash & Short-Term Investments $9.19M $18.90M
Total Current Assets $14.15M $21.45M
Total Non-Current Assets $0 $0
Total Assets $14.15M $21.45M
Accounts Payable $3.89M $776K
Total Current Liabilities $6.66M $912K
Total Non-Current Liabilities $0 $0
Total Liabilities $6.66M $912K
Common Stock $81 $81
Retained Earnings -$21.76M -$8.32M
Total Stockholders' Equity -$20.66M -$7.78M
Total Equity -$20.66M -$7.78M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

No annual cash flow statement rows are available in SEC EDGAR CompanyFacts for RTSN.

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Net Income -$5.92M -$4.14M -$3.38M -$1.48M -$1.23M -$656K

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

No annual ratios & growth rows are available in SEC EDGAR CompanyFacts for RTSN.

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Current Ratio 2.12x -- -- -- -- --
Quick Ratio 1.38x -- -- -- -- --
Source: SEC EDGAR CompanyFacts (CIK 0002002988) · from March 31, 2025 Data through September 30, 2026 · synced Nov 20, 2026, 05:53 UTC · Open in terminal